Results 111 to 120 of about 2,655 (208)

Effectiveness of galcanezumab on sleep quality, migraine outcome, and multidimensional patient-reported outcome measures: a real-world experience in Turkish patients with episodic and chronic migraine

Frontiers in Neurology
IntroductionThis real-world study aimed to investigate the impact of galcanezumab on sleep quality, migraine outcome and multidimensional patient-reported outcomes measures (PROMs) in patients with episodic migraine (EM) and chronic migraine (CM ...
Elif Ilgaz Aydinlar, Tuba Erdogan Soyukibar, Pinar Yalinay Dikmen   +2 more
doaj   +1 more source

Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine

Patient Preference and Adherence, 2018
Janet H Ford,1 Shonda A Foster,1 Virginia L Stauffer,1 Dustin D Ruff,1 Sheena K Aurora,1 Jan Versijpt2 1Eli Lilly and Company, Indianapolis, IN 46225, USA; 2Department of Neurology – Headache and Facial Pain Clinic, Vrije Universiteit Brussel (VUB)
Ford JH, Foster SA, Stauffer VL, Ruff DD, Aurora SK, Versijpt J   +5 more
doaj  

Comparison between prefilled syringe and autoinjector devices on patient-reported experiences and pharmacokinetics in galcanezumab studies

Patient Preference and Adherence, 2018
Virginia L Stauffer,1 Ryan Sides,1 Michel Lanteri-Minet,2,3 William Kielbasa,1 Yan Jin,1 Katherine J Selzler,1 Stewart J Tepper4 1Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA; 2Pain Department, CHU Nice, Nice, France ...
Stauffer VL, Sides R, Lanteri-Minet M, Kielbasa W, Jin Y, Selzler KJ, Tepper SJ   +6 more
doaj  

Normal delivery following use of galcanezumab until the first and second trimesters of pregnancy: A report of 2 cases. [PDF]

Medicine (Baltimore)
Akiyama H, Yamano Y.
europepmc   +1 more source

Could galcanezumab modulate inflammatory cytokines? A single-centre exploratory study. [PDF]

J Neurol
Ceccardi G, Rao R, Schiano di Cola F, Fiducia B, Tolassi C, Quaresima V, Mattioli I, Eshja K, Cresta E, Gipponi S, Pilotto A, Padovani A.   +11 more
europepmc   +1 more source

Galcanezumab for migraine [PDF]

Australian Prescriber, 2020
openaire   +2 more sources

Prescriber adherence to treatment guidelines for monoclonal antibodies against Calcitonin Gene-Related Peptide in migraine prophylaxis - a register-based cohort study. [PDF]

J Headache Pain
Nordenmalm S, Malmström RE, Freyland S, Nilsson Remahl AIM, Wirdefeldt K, Ekheden I.   +5 more
europepmc   +1 more source

Anti-CGRP receptor antibodies do not modulate trigeminal pain processing: indication for distinct mechanisms of CGRP pathway blockade. [PDF]

J Headache Pain
Peng KP, Basedau H, Messlinger K, May A.
europepmc   +1 more source

Twelve-month efficacy of CGRP monoclonal antibodies and predictive value of short-term response: Results of an Australian multicentre study [PDF]

Introduction Clinical trials show that calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) are effective preventative treatments for chronic migraine.
Baker, J, Cheng, S, Dalic, L, Hutton, EJ, Matharu, M, Ray, JC   +5 more
core  

Comparative effectiveness and safety of preventive treatments for vestibular migraine: a systematic review and network meta-analysis. [PDF]

BMC Neurol
Vasireddy S, Biswas S, Kollu R, Krishnan E, Khan MS, C F, Jayakumar A, Acharya R.   +7 more
europepmc   +1 more source